Literature DB >> 28176268

No genetic association between attention-deficit/hyperactivity disorder (ADHD) and Parkinson's disease in nine ADHD candidate SNPs.

Julia M Geissler1, Marcel Romanos2, Manfred Gerlach2, Daniela Berg3,4,5, Claudia Schulte3,4.   

Abstract

Attention-deficit/hyperactivity disorder (ADHD) and Parkinson's disease (PD) involve pathological changes in brain structures such as the basal ganglia, which are essential for the control of motor and cognitive behavior and impulsivity. The cause of ADHD and PD remains unknown, but there is increasing evidence that both seem to result from a complicated interplay of genetic and environmental factors affecting numerous cellular processes and brain regions. To explore the possibility of common genetic pathways within the respective pathophysiologies, nine ADHD candidate single nucleotide polymorphisms (SNPs) in seven genes were tested for association with PD in 5333 cases and 12,019 healthy controls: one variant, respectively, in the genes coding for synaptosomal-associated protein 25 k (SNAP25), the dopamine (DA) transporter (SLC6A3; DAT1), DA receptor D4 (DRD4), serotonin receptor 1B (HTR1B), tryptophan hydroxylase 2 (TPH2), the norepinephrine transporter SLC6A2 and three SNPs in cadherin 13 (CDH13). Information was extracted from a recent meta-analysis of five genome-wide association studies, in which 7,689,524 SNPs in European samples were successfully imputed. No significant association was observed after correction for multiple testing. Therefore, it is reasonable to conclude that candidate variants implicated in the pathogenesis of ADHD do not play a substantial role in PD.

Entities:  

Keywords:  ADHD; CDH13; Dopamine transporter; GWAS; Parkinson’s disease; SNPs

Mesh:

Year:  2017        PMID: 28176268      PMCID: PMC6233883          DOI: 10.1007/s12402-017-0219-8

Source DB:  PubMed          Journal:  Atten Defic Hyperact Disord        ISSN: 1866-6116


  35 in total

Review 1.  Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease.

Authors:  Jennifer G Goldman; Neelum T Aggarwal; Cynthia D Schroeder
Journal:  Neurodegener Dis Manag       Date:  2015-10-30

Review 2.  Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.

Authors:  James E Galvin
Journal:  Acta Neuropathol       Date:  2006-06-22       Impact factor: 17.088

Review 3.  Parkinson's disease.

Authors:  Lorraine V Kalia; Anthony E Lang
Journal:  Lancet       Date:  2015-04-19       Impact factor: 79.321

Review 4.  Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder.

Authors:  C Mehler-Wex; P Riederer; M Gerlach
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

5.  Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis.

Authors:  Paolo Fusar-Poli; Katya Rubia; Giorgio Rossi; Giuseppe Sartori; Umberto Balottin
Journal:  Am J Psychiatry       Date:  2012-03       Impact factor: 18.112

6.  Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings.

Authors:  D Berg; C Siefker; G Becker
Journal:  J Neurol       Date:  2001-08       Impact factor: 4.849

7.  Genome-wide association scan of quantitative traits for attention deficit hyperactivity disorder identifies novel associations and confirms candidate gene associations.

Authors:  Jessica Lasky-Su; Benjamin M Neale; Barbara Franke; Richard J L Anney; Kaixin Zhou; Julian B Maller; Alejandro Arias Vasquez; Wai Chen; Philip Asherson; Jan Buitelaar; Tobias Banaschewski; Richard Ebstein; Michael Gill; Ana Miranda; Fernando Mulas; Robert D Oades; Herbert Roeyers; Aribert Rothenberger; Joseph Sergeant; Edmund Sonuga-Barke; Hans Christoph Steinhausen; Eric Taylor; Mark Daly; Nan Laird; Christoph Lange; Stephen V Faraone
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-12-05       Impact factor: 3.568

8.  Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease.

Authors:  Dao-Ying Geng; Yu-Xin Li; Chi-Shing Zee
Journal:  Neurosurgery       Date:  2006-02       Impact factor: 4.654

9.  Structural abnormality of the substantia nigra in children with attention-deficit hyperactivity disorder.

Authors:  Marcel Romanos; David Weise; Mira Schliesser; Martin Schecklmann; Julia Löffler; Andreas Warnke; Manfred Gerlach; Joseph Classen; Claudia Mehler-Wex
Journal:  J Psychiatry Neurosci       Date:  2010-01       Impact factor: 6.186

Review 10.  A review of executive function deficits in autism spectrum disorder and attention-deficit/hyperactivity disorder.

Authors:  Francesco Craig; Francesco Margari; Anna R Legrottaglie; Roberto Palumbi; Concetta de Giambattista; Lucia Margari
Journal:  Neuropsychiatr Dis Treat       Date:  2016-05-12       Impact factor: 2.570

View more
  3 in total

1.  Increased risk of diseases of the basal ganglia and cerebellum in patients with a history of attention-deficit/hyperactivity disorder.

Authors:  Karen Curtin; Annette E Fleckenstein; Brooks R Keeshin; Deborah A Yurgelun-Todd; Perry F Renshaw; Ken R Smith; Glen R Hanson
Journal:  Neuropsychopharmacology       Date:  2018-09-12       Impact factor: 7.853

2.  Association study and a systematic meta-analysis of the VNTR polymorphism in the 3'-UTR of dopamine transporter gene and attention-deficit hyperactivity disorder.

Authors:  Edna Grünblatt; Anna Maria Werling; Alexander Roth; Marcel Romanos; Susanne Walitza
Journal:  J Neural Transm (Vienna)       Date:  2019-03-28       Impact factor: 3.575

Review 3.  Stimulant Induced Movement Disorders in Attention Deficit Hyperactivity Disorder.

Authors:  Seok-Hyun Nam; Myung Ho Lim; Tae Won Park
Journal:  Soa Chongsonyon Chongsin Uihak       Date:  2022-04-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.